Abivax Posts Negative P/E of -33.83 with Phase 3 Results Due Q2 2026
Abivax operates with a negative P/E of -33.83 and a 725.84 price-to-sales ratio, reflecting unprofitability despite high investor valuations. Its lead drug obefazimod is in phase 3 ulcerative colitis trials with pivotal maintenance results expected by late Q2 2026, while revenue projections stand at $1.55 million.
1. Financial Metrics Highlight Unprofitability
Abivax reports a negative P/E ratio of -33.83 alongside a price-to-sales ratio of 725.84, underscoring current losses and a premium valuation. Its enterprise value to sales ratio of 728.35 and an EV to operating cash flow ratio of -50.61 highlight substantial cash-generation challenges.
2. Obefazimod Progress in Phase 3 Trials
The company’s lead candidate, obefazimod, employing a mir-124 enhancer mechanism, is advancing through phase 3 trials for ulcerative colitis. Successful induction and maintenance data would position Abivax’s differentiated therapy as a key asset in chronic inflammatory disease treatment.
3. Strategic Investor Acquisitions Signal Confidence
Institutional investors have increased their stakes, including a purchase of 14,000 shares valued at $1.2 million by Bamco Inc. Additional buys by EverSource Wealth Advisors and First Horizon Corp. highlight market confidence in Abivax’s pipeline potential.
4. Upcoming Catalysts and Revenue Projections
Abivax is set to release quarterly earnings with projected EPS of -$1.35 and revenue of $1.55 million. Pivotal obefazimod maintenance results are expected by late Q2 2026, alongside phase 2b Crohn’s disease induction data, providing near-term catalysts.